Literature DB >> 2731651

A developmental study of the abnormal expression of alpha-cardiac and alpha-skeletal actins in the striated muscle of a mutant mouse.

I Garner1, D Sassoon, J Vandekerckhove, S Alonso, M E Buckingham.   

Abstract

BALB/c mice possess a 5' duplication of the alpha-cardiac actin gene which is associated with abnormal levels of alpha-cardiac and alpha-skeletal actin mRNAs in adult cardiac tissue. This mutation therefore provides a potential tool for the study of the inter-relationship between the striated muscle actins. We have examined the expression of this actin gene pair throughout the development of skeletal and cardiac muscle in BALB/c mice. During embryonic and fetal development, the expression of these two genes is indistinguishable from that in normal mice, as determined by in situ hybridization. A quantitative postnatal study demonstrates that in the hearts of normal mice the level of alpha-cardiac actin mRNA declines, whereas that of alpha-skeletal actin increases. In mutant mice, these trends are exaggerated so that whereas normal mice have 95.8% alpha-cardiac mRNA and 4.2% alpha-skeletal mRNA in the adult heart, BALB/c mice have 52.4 and 47.6% of these mRNAs, respectively. This difference is also reflected at the protein level. In developing skeletal muscle, the expression of these genes follows kinetics similar to that observed in the heart with a decrease in the relative level of alpha-cardiac mRNA as the muscle matures. Cardiac actin mRNA levels are again lower in the mutant mouse, but here the effect is less striking because skeletal actin is the predominant isoform. These results are discussed in the context of the interaction between this actin gene pair in developing and adult striated muscle.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731651     DOI: 10.1016/0012-1606(89)90093-6

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  8 in total

1.  Notochordal and foregut abnormalities correlate with elevated neural crest apoptosis in Patch embryos.

Authors:  Paige Snider; Olga Simmons; Rhonda Rogers; Rachel Young; Mica Gosnell; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-05-06

2.  The c-myc proto-oncogene regulates cardiac development in transgenic mice.

Authors:  T Jackson; M F Allard; C M Sreenan; L K Doss; S P Bishop; J L Swain
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

3.  Transgenic overexpression of cardiac actin in the mouse heart suggests coregulation of cardiac, skeletal and vascular actin expression.

Authors:  A Kumar; K Crawford; R Flick; R Klevitsky; J N Lorenz; K E Bove; J Robbins; J L Lessard
Journal:  Transgenic Res       Date:  2004-12       Impact factor: 2.788

4.  Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes.

Authors:  M Buvoli; A Buvoli; L A Leinwand
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

5.  Novel muscle-specific enhancer sequences upstream of the cardiac actin gene.

Authors:  C Biben; B J Kirschbaum; I Garner; M Buckingham
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

6.  Denervated chicken breast muscle displays discoordinate regulation and differential patterns of expression of alpha f and beta tropomyosin genes.

Authors:  M P Gupta; R J Wiesner; V Mouly; R Zak; M Lemonnier
Journal:  J Muscle Res Cell Motil       Date:  1993-08       Impact factor: 2.698

7.  A novel complex regulates cardiac actin gene expression through interaction of Emb, a class VI POU domain protein, MEF2D, and the histone transacetylase p300.

Authors:  S Molinari; F Relaix; M Lemonnier; B Kirschbaum; B Schäfer; M Buckingham
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

8.  The vascular smooth muscle alpha-actin gene is reactivated during cardiac hypertrophy provoked by load.

Authors:  F M Black; S E Packer; T G Parker; L H Michael; R Roberts; R J Schwartz; M D Schneider
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.